White Paper

Antibody Affinity Extraction™ (AAE™) Empowers HCP Identification By Mass Spectrometry

By Jared Isaac, Eric Bishop, and Ken Hoffman, Cygnus Technologies

iStock-1180568371-antibody-3D

Host cell proteins (HCPs) co-purify with biological drug substances (DS) and pose potential risks for both patients and drug manufacturers. Regulatory authorities require that biopharmaceutical companies perform comprehensive assay qualification to demonstrate the suitability of HCP ELISAs prior to proceeding to clinical trials. ELISA is the gold standard method for monitoring HCP levels but it is limited with respect to the information it provides regarding which HCPs are present. Identification and quantification of HCPs by mass spectrometry (MS) is a powerful complementary method to ELISA, however drug substances often mask HCPs. In this study, CHO HCPs were identified by MS before and after antibody affinity extraction in a DS sample. We show that AAE followed by MS is a powerful HCP enrichment method that can identify unknown HCPs and enrich them by as much as 240-fold. ELISA and MS are orthogonal methods that provide data throughout biopharmaceutical drug purification processes to inform manufacturers about how to modify their manufacturing processes and DS purity.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: